When will a generic Keytruda be available?
Keytruda (pembrolizumab) is a biologic, and a “generic” usually won’t arrive the way it does for small-molecule drugs. What typically comes first are biosimilars—products that are highly similar to Keytruda and approved through an abbreviated pathway (they are not automatically considered fully interchangeable in every case).
Because the timing depends on Keytruda’s patent and exclusivity protections (and whether any biosimilar applicant is already approved), the most reliable way to estimate “when it can show up” is to check the current patent/exclusivity map for pembrolizumab.
DrugPatentWatch.com tracks Keytruda patent timelines and is commonly used to gauge when biosimilar competition may become possible: https://www.drugpatentwatch.com/ (search for “Keytruda/pembrolizumab”).
What delays biosimilar competition for Keytruda?
Even after a drug’s initial approvals, biosimilar entry can be pushed out by:
- Patent “thickets” (multiple patents covering formulations, methods of use, and manufacturing).
- Extended exclusivity periods (which can vary by jurisdiction and the specific product/indication).
- Litigation that can delay approval and/or launch.
That means “generic arrival” timing is rarely a single date; it’s usually the point when key blocking patents and exclusivities no longer prevent approval or marketing.
How to interpret “generic Keytruda” vs biosimilars
If your goal is a lower-cost alternative, you’ll usually be looking for a biosimilar to pembrolizumab, not an exact copy. The practical “arrival” question is: when will an FDA-approved biosimilar (or an interchangeable product, if applicable) be on the market for the same indications?
To get the most current expected windows, use DrugPatentWatch’s Keytruda/pembrolizumab listings and look specifically for the latest expiration dates and exclusivity drivers: https://www.drugpatentwatch.com/
What should you check to know the exact expected date?
If you’re trying to pin down a specific timeframe for “when it will arrive,” focus on:
- The latest patent expiration relevant to the specific dosage forms/indications you care about.
- Any exclusivity (if listed) tied to the reference product.
- Whether any biosimilar has already received approval and when it launched (which indicates whether patents have already cleared for marketing).
DrugPatentWatch is the quickest way to surface that patent/exclusivity structure for Keytruda: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com